Please assess the completion status of the following clinical trial:

Trial Title: Can Presumptive Anthelminthic Treatment Delay the Progression of HIV in ART-naïve Patients in Rural Africa?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-positive patients~* most recent CD4-count \> 250 c/μl (latest within the previous 7 months)~* anti-retroviral treatment naïve~* age \>18 years~* provide written informed consent~Exclusion Criteria:~* Pregnant and lactating women in the first week of lactation~* Symptoms of severe anemia (or haemoglobin \<5g/dl within the precious 3 months)~* Symptoms of chronic diarrhea (defined as \>= 3 stools per day of loose consistency for more than 2 weeks)~* Patients on treatment for tuberculosis~* WHO clinical stage 3 disease and CD4-count \<350 c/μl~* WHO clinical stage 4 disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- anthelminthic treatment (Type: ACTIVE_COMPARATOR): Albendazol plus fix-dose Praziquantel plus Ivermectin
- HIV care, no anthelminthic treatment (Type: NO_INTERVENTION): HIV care as per Tanzanian National AIDS Control Program (NACP) guidelines

Based on this trial design, predict the completion outcome and termination type (if applicable).